GlassScriptPhysician profile
Elizabeth Young
NPI 1871045914
$4,948.95
in general payments reported to CMS, 2019-2025
40 companies · $935 in 2025
The $935 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,835 · 2022: $983 · 2023: $471 · 2024: $724 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.44 | 2021-2025 | |
| Lilly USA, LLC | $571.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $502.05 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $376.11 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $353.42 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $280.39 | 2021-2025 | Eliquis |
| Amarin Pharma, INC. | $277.12 | 2021-2022 | |
| Abbott Laboratories | $243.82 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.58 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $132.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $130.42 | 2021-2025 | Verquvo, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $128.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $128.84 | 2021-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $79.59 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $75.81 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.